These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 28835385

  • 1. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
    Kraus D, Palasuberniam P, Chen B.
    Mol Cancer Ther; 2017 Nov; 16(11):2422-2431. PubMed ID: 28835385
    [Abstract] [Full Text] [Related]

  • 2. Combination of phosphatidylinositol 3-kinases pathway inhibitor and photodynamic therapy in endothelial and tumor cells.
    Fateye B, Li W, Wang C, Chen B.
    Photochem Photobiol; 2012 Nov; 88(5):1265-72. PubMed ID: 22506666
    [Abstract] [Full Text] [Related]

  • 3. Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
    Fateye B, Wan A, Yang X, Myers K, Chen B.
    Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):19-26. PubMed ID: 25636781
    [Abstract] [Full Text] [Related]

  • 4. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
    Valentino JD, Li J, Zaytseva YY, Mustain WC, Elliott VA, Kim JT, Harris JW, Campbell K, Weiss H, Wang C, Song J, Anthony L, Townsend CM, Evers BM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1212-22. PubMed ID: 24443523
    [Abstract] [Full Text] [Related]

  • 5. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.
    Cancer Chemother Pharmacol; 2012 Jun 01; 69(6):1601-15. PubMed ID: 22543857
    [Abstract] [Full Text] [Related]

  • 6. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
    Chanal M, Chevallier P, Raverot V, Fonteneau G, Lucia K, Monteserin Garcia JL, Rachwan A, Jouanneau E, Trouillas J, Honnorat J, Auger C, Theodoropoulou M, Raverot G.
    Mol Cancer Ther; 2016 Jun 01; 15(6):1261-70. PubMed ID: 26983879
    [Abstract] [Full Text] [Related]

  • 7. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
    Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.
    Oncotarget; 2014 Aug 30; 5(16):6788-800. PubMed ID: 25216518
    [Abstract] [Full Text] [Related]

  • 8. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.
    Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.
    Mol Cancer Ther; 2017 Apr 30; 16(4):637-648. PubMed ID: 28119489
    [Abstract] [Full Text] [Related]

  • 9. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
    Bonelli MA, Cavazzoni A, Saccani F, Alfieri RR, Quaini F, La Monica S, Galetti M, Cretella D, Caffarra C, Madeddu D, Frati C, Lagrasta CA, Falco A, Rossetti P, Fumarola C, Tiseo M, Petronini PG, Ardizzoni A.
    Mol Cancer Ther; 2015 Aug 31; 14(8):1916-27. PubMed ID: 26013318
    [Abstract] [Full Text] [Related]

  • 11. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S.
    Clin Cancer Res; 2014 Sep 15; 20(18):4849-60. PubMed ID: 25070836
    [Abstract] [Full Text] [Related]

  • 12. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M, Fulda S.
    Cancer Lett; 2015 Apr 28; 360(1):1-9. PubMed ID: 25637161
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic Enhancement of Verteporfin-mediated Photodynamic Therapy by mTOR Inhibitors.
    Kraus D, Palasuberniam P, Chen B.
    Photochem Photobiol; 2020 Mar 28; 96(2):358-364. PubMed ID: 31769520
    [Abstract] [Full Text] [Related]

  • 14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 15. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE.
    Breast Cancer Res; 2013 Jan 23; 15(1):R8. PubMed ID: 23343422
    [Abstract] [Full Text] [Related]

  • 16. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.
    Mol Cancer Ther; 2012 Feb 23; 11(2):317-28. PubMed ID: 22188813
    [Abstract] [Full Text] [Related]

  • 17. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 18. In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance.
    Anisuzzaman AS, Haque A, Wang D, Rahman MA, Zhang C, Chen Z, Chen ZG, Shin DM, Amin AR.
    Mol Cancer Ther; 2017 Apr 01; 16(4):729-738. PubMed ID: 28119490
    [Abstract] [Full Text] [Related]

  • 19. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP, Reynolds CP, Kang MH.
    Clin Cancer Res; 2016 Feb 01; 22(3):621-32. PubMed ID: 26080839
    [Abstract] [Full Text] [Related]

  • 20. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 01; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.